Grifols has filed a patent for a method to reduce the frequency of administering anti-VEGF agents to patients with wet age-related macular degeneration. The method involves administering a CCR3 inhibitory agent before the anti-VEGF agent and subsequently administering the anti-VEGF agent at a lower frequency than recommended. This method aims to treat patients with retina-associated diseases more effectively. GlobalData’s report on Grifols gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Grifols SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Grifols, Attenuated virus-based vaccines was a key innovation area identified from patents. Grifols's grant share as of September 2023 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Method for reducing frequency of anti-vegf agent administration

Source: United States Patent and Trademark Office (USPTO). Credit: Grifols SA

A recently filed patent (Publication Number: US20230312697A1) describes a method for reducing the frequency of administration of an anti-VEGF agent to patients diagnosed with wet age-related macular degeneration (AMD). The method involves administering a CCR3 inhibitory agent to the patient, followed by the administration of the anti-VEGF agent. Subsequent doses of the anti-VEGF agent are then administered at a frequency lower than the recommended frequency.

The CCR3 inhibitory agent can be a CCR3 antagonist or an Eotaxin-1 antagonist. In one embodiment, the CCR3 antagonist is a small molecule, such as Compound 1. The anti-VEGF agent used in the method is an antibody or antibody fragment that selectively binds to vascular endothelial growth factor (VEGF). Examples of such antibodies include bevacizumab and ranibizumab. Alternatively, a recombinant fusion protein like aflibercept can be used as the anti-VEGF agent.

The frequency of administering subsequent doses of the anti-VEGF agent is less than the recommended frequency, which can be less than seven doses every twelve months, less than one dose every three months, or less than one dose every two months. The administration of the anti-VEGF agent to the patient is typically performed intravitreally.

In another aspect of the patent, the method includes determining whether to administer additional subsequent doses of the anti-VEGF agent by diagnosing a morphological change in the eye of the patient with wet AMD. Clinically relevant morphological changes that may indicate the need for additional doses include increased intraretinal fluid, increased choroidal neovascularization, and increased central retinal pigment epithelium detachment height.

The patent also describes a method for treating patients suffering from retina-associated diseases who have previously been treated with a CCR3 inhibitory agent. The anti-VEGF agent is administered at a frequency lower than the recommended frequency. The CCR3 inhibitory agent can be a CCR3 antagonist or an Eotaxin-1 antagonist, and the anti-VEGF agent can be an antibody or antibody fragment, or a recombinant fusion protein.

Overall, this patent presents a method for reducing the frequency of administration of anti-VEGF agents to patients with wet AMD, potentially improving treatment outcomes and reducing the burden on patients and healthcare providers.

To know more about GlobalData’s detailed insights on Grifols, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies